Topical ruxolitinib cream 1.5% for 24 weeks was significantly associated with disease improvement among patients with prurigo nodularis.

Delgocitinib cream 20mg/g significantly improves the sign and symptoms of chronic hand eczema among adolescent patients compared with vehicle cream.

High doses of temtokibart — including 600 mg, 450 mg, and 300 mg — contributed to significant improvements in disease severity in patients with AD.

Levels of systemic inflammatory markers were reduced following 16 weeks of secukinumab treatment in patients with moderate to severe HS.